BIO

For research use only. Not for use in humans.

目录号:S7198 别名: GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052

BIO Chemical Structure

CAS No. 667463-62-9

BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052)是一种特异性的GSK-3抑制剂,无细胞试验中作用于GSK-3α/β的IC50为5 nM,比作用于CDK5选择性高16倍以上,也是一种泛JAK抑制剂,对 Tyk2 的IC50值为30 nM。BIO 可在人类黑色素瘤细胞中诱导凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1286.64 现货
RMB 1206.72 现货
RMB 4671.57 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的BIO发表文献24篇:

产品安全说明书

GSK-3抑制剂选择性比较

生物活性

产品描述 BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052)是一种特异性的GSK-3抑制剂,无细胞试验中作用于GSK-3α/β的IC50为5 nM,比作用于CDK5选择性高16倍以上,也是一种泛JAK抑制剂,对 Tyk2 的IC50值为30 nM。BIO 可在人类黑色素瘤细胞中诱导凋亡。
特性 BIO是第一个维持人类和小鼠的胚胎干细胞自我更新的药理剂。
靶点
GSK-3 [1]
(Cell-free assay)
TYK2 [4]
(Cell-free assay)
CDK5/p35 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
CDK1/CyclinB [1]
(Cell-free assay)
5 nM 30 nM 0.08 μM 0.30 μM 0.32 μM
体外研究

BIO (6-bromoindirubin-3'-oxime)是特异性的GSK-3抑制剂,作用于GSK-3α/β,IC50为5 nM,比作用于CDK5选择性高16倍以上。BIO与这些激酶的ATP结合口袋相互作用,降低β-catenin在GSK-3特异性位点磷酸化。[1]BIO作用于人类和小鼠胚胎干细胞,保持未分化表型,并维持多能状态特异性的转录表达因子Oct-3/4, Rex-1 和 Nanog表达。BIO-介导的Wnt信号激活是功能可逆的,撤掉化合物后,导致人类和小鼠胚胎干细胞的正常多元分化程序。[2]BIO促进哺乳动物心肌细胞增殖。[3] BIO也是pan-JAK抑制剂,作用于TYK2, JAK1, JAK2 和 JAK3,IC50值分别为0.03, 1.5, 8.0, 0.5 μM。BIO选择性抑制STAT3磷酸化,且诱导人类黑色素瘤细胞凋亡。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEI-OC1 MnPOSpVv[3Srb36gZZN{[Xl? MXfQdo91\WO2aX;uJIFo[Wmwc4SgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bEBqdiCwZX;uZZRidCCvb4Xz[UBJTUlvT1OxJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClYYPwZZNmNTNxNzDhZ5Rqfmm2eTygSWM2OCB;IECuNVkzKM7:TT6= NEeze|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC5NVkyPSd-M{CwPVE6OTV:L3G+
SH-SY5Y MV;GeY5kfGmxbjDhd5NigQ>? NGrJdmNKdmirYnn0bY9vKG:oIFfTT|MudWWmaXH0[YQh[mW2YT3jZZNmcW5icHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFOKLWPZOXkh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiTVexN|Ih[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzMEBKSzVyIE2gNE4zQSEQvF2u MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDhzNkGxNEc,OTh6MU[xNVA9N2F-
K562 M3G1emFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NE\FZpE4OiCqcoO= MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwMzFOwG0v MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd6M{G0PUc,OTl5OEOxOFk9N2F-
IMR90 NVzsXo1ESW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M4fNVVczKGi{cx?= M2G1UWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSV3SPVAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuPUDPxE1w NF7EdVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe4N|E1QSd-MUm3PFMyPDl:L3G+
HCT116 Mm\tRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NF3VSos4OiCqcoO= M2X1NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC1MlIh|ryPLh?= NV;qPGx2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O|g{OTR7PD;hQi=>
HepG2 NF[wNoJEgXSxdH;4bYNqfHliYYPzZZk> MnThNlQhcHK| MnXtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjCyOEBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTBiPTC1MlMh|ryPLh?= MlH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEO0PVIoRjJ6N{SzOFkzRC:jPh?=
HL60 NGfQU49CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M{f1fVUh\GG7cx?= MnXGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDViZHH5d{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3LkSg{txONg>? MmjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5OEOxOFkoRjF7N{izNVQ6RC:jPh?=
HuH7 MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NXe3RmxUPzJiaILz MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi3SEegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDZwMjFOwG0v NGXpWoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe4N|E1QSd-MUm3PFMyPDl:L3G+
SH-SY5Y NWrIZ4xuS3m2b4TvfIlkcXS7IHHzd4F6 NFzw[I41QCCqcoO= NHvlN45EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGOgdoVlfWO2aX;uJIF{e2G7LDDJR|UxKD1iOTFOwG0v M2\yc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OEG2NVExLz5zOEixOlEyODxxYU6=
SH-SY5Y M4TN[mZ2dmO2aX;uJIF{e2G7 NY\TN2RNPDhiaILz NFntU21UfXK4aY\hcEBw\iCqdX3hckBUUC2VWUXZJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGOgdoVlfWO2aX;uJIF{e2G7LDDJR|UxKD1iOT61JO69VS5? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjh3NEC2PUc,OTZ6NUSwOlk9N2F-
SH-SY5Y NWHzeGV[TnWwY4Tpc44h[XO|YYm= M4PkVmRm[XSqIH;mJIh2dWGwIGPIMXN[PVliY3XscJMhcW5iYXLz[Y5k\SCxZjCyNEB2VSCTLW\EMW9RcCCkeTDNWHMhemWmdXP0bY9vKGG|c3H5MEBKSzVyIE2gNVAh|ryPLh?= M{XVdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY6Lz5zNki1OFA3QTxxYU6=
SH-SY5Y NHTwN2FHfW6ldHnvckBie3OjeR?= MWLE[YF1cCCxZjDoeY1idiCVSD3TXVV[KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJJVOKFFvVlStU3BpKGK7IF3UV{Bz\WS3Y4Tpc44h[XO|YYmsJGlEPTBiPTCxN{DPxE1w M3fVeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY6Lz5zNki1OFA3QTxxYU6=
SH-SY5Y MV;GeY5kfGmxbjDhd5NigQ>? NXPlepB7OjRiaILz NG[yOHNUfXK4aY\hcEBw\iCqdX3hckBUUC2VWUXZJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCPVGOgdoVlfWO2aX;uJIF{e2G7LDDJR|UxKD1iMUig{txONg>? NYjuVIZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4OVQxPjlpPkG2PFU1ODZ7PD;hQi=>
IMR32 NGr2NG1EgXSxdH;4bYNqfHliYYPzZZk> Mnv1OFghcHK| Mn76R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTW1TOzJiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfS=> NWrhcJlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFI6PDdpPkKxPFAzQTR5PD;hQi=>
SK-N-SH M1n1e2N6fG:2b4jpZ4l1gSCjc4PhfS=> MYe0PEBpenN? NIrwOHREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLWPIJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[Xl? MnLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEK5OFcoRjJzOECyPVQ4RC:jPh?=
NB39 MojBR5l1d3SxeHnjbZR6KGG|c3H5 M4rqcVQ5KGi{cx?= MlvpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmI{QSClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5 M1HYUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOECyPVQ4Lz5{MUiwNlk1PzxxYU6=
A673 NFS1epByUFSVIHHzd4F6 MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? NHTCXnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY MVXxTHRUKGG|c3H5 M4\EXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| MkP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 NGfablByUFSVIHHzd4F6 NUfEVpl7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> M{LxT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 NXL4[lFieUiWUzDhd5NigQ>? M4XMR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= NWHJVWtkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD Mny0dWhVWyCjc4PhfS=> M{L3e5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NWnJe4ZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH MVHxTHRUKGG|c3H5 MoPHdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NF\hWWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 MlyxdWhVWyCjc4PhfS=> NFj0bZlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= Mke4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) M4Dw[pFJXFNiYYPzZZk> NVjIU4FDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz NEHINWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NGe0dlNyUFSVIHHzd4F6 NVjMVFN4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> NG\vO449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MnfndWhVWyCjc4PhfS=> MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| MlnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 MUjxTHRUKGG|c3H5 NHPpWoxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= MoXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 MlfWdWhVWyCjc4PhfS=> NGfYO|JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= NXT1bZRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NUXuUWhmeUiWUzDhd5NigQ>? NUjOZWlLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> M2i0[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MVnxTHRUKGG|c3H5 MonFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= NYfEdYVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 NVT4c|k4eUiWUzDhd5NigQ>? M{P2Z5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz Mn3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 MmrudWhVWyCjc4PhfS=> MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? NV;ablh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 M2TNZ5FJXFNiYYPzZZk> MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NXztTXM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A549 NVvkeYZsTnWwY4Tpc44h[XO|YYm= NX3YVpNGOTBidV2= MnT2NVUhdWmwcx?= MU\Jcohq[mm2aX;uJI9nKGi3bXHuJI1RT0WVMTDmdo9uKGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiUFfFNkBifCBzMDD1UUBi\nSncjCxOUBucW6|IHL5JGhRVEN? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ7N{K0OEc,OjR4OUeyOFQ9N2F-
HEK293 NHLmenBHfW6ldHnvckBie3OjeR?= MXOwMlUhfG9iMTD1US=> MlnuTY5pcWKrdHnvckBw\iCqdX3hckBIW0t|IHHjeIl3cXS7IHnuJGhGUzJ7MzDj[YxteyClb370ZYlvcW6pIITo[UBYdnRxYnX0ZU1k[XSnbnnuJIFkfGm4YYTl[EBz\XCxcoTldkBxW3WyZYLUU3BHVEGVSDCoV3RHOjl|IHPlcIx{MSCjdDCwMlUhfG9iMTD1UUBjgSCZboSgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> NVzPblN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PVczPDRpPkK0Olk4OjR2PD;hQi=>
sf9 NUXQbI8{TnWwY4Tpc44h[XO|YYm= NGTwfYYyKHWP MofJTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPCBqU{SgeI8hTTNyMzDy[ZNq\HWnczmvR5lkdGmwIFSxJEhSPCC2bzDJNlk2KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gd4Y6KGOnbHzzJIF1KDFidV2geZNqdmdiUlKtR3RHKGG|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>? NGntb2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 MkLSSpVv[3Srb36gZZN{[Xl? M335ZVEhfU1? M1H5dWlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SvTIl{Pi22YXfn[YQhT1ONM3LleIEhME1zIITvJHQ1OjBicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC|ZkmgZ4VtdHNiYYSgNUB2VSC3c3nu[{BTSkWULVnSV5Rq\GViYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7 MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 NYr2[nRXTnWwY4Tpc44h[XO|YYm= Mmi0NUB2VQ>? NU\H[FJGUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNMjCoUVEhfG9iTEK5PEBz\XOrZIXld{kwS3mlbHnuJGEzKCiPMTD0c{BNPDN{IILld4llfWW|KTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy|IHH0JFEhfU1idYPpcochUGm|dH;u[UBJOSCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 M1Ts[WZ2dmO2aX;uJIF{e2G7 NYD2V5ZZOSC3TR?= MXPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGs2KCiPMTD0c{BROjl{IILld4llfWW|KT;wN|VPS0tiKF2xJJRwKFJ|MEegdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDz[lkh[2WubIOgZZQhOSC3TTD1d4lv\yCUQj3DWGYh[XNic4Xid5Rz[XSnIHL5JIZqdHSncjDibY5lcW6pIHHzd4F6 NH7ReZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 M2LYb2Z2dmO2aX;uJIF{e2G7 M4H4WFEhfU1? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG4ufGW{bXnuZYwhT1OWL1jpd|YufGGpZ3XkJGF2em:{YTDCJEhCOiC2bzDBN|Q1KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gd4Y6KGOnbHzzJIF1KDFidV2geZNqdmdidHX0doEpVFKUTGPMS{kh[XNic4Xid5Rz[XSnIHL5JIZqdHSncjDibY5lcW6pIHHzd4F6 NYfQeZFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 MVHGeY5kfGmxbjDhd5NigQ>? Mm\pNUB2VQ>? M2PMemlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SvTIl{Pi22YXfn[YQhTkeIUkGgLGc1ODBidH:gVlgzOCC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoOTDj[YxteyCjdDCxJJVOKHW|aX7nJHBwdHlqR3z1MHR6eil2OkGgZZMhe3Wkc4TyZZRmKGK7IH\pcJRmeiCkaX7kbY5oKGG|c3H5 MoThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
sf9 MXrGeY5kfGmxbjDhd5NigQ>? NFLRbZcyKHWP MmDITY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE9JcXN4LYTh[4dm\CCFRFuxJEhOOSC2bzDNNlk4KHKnc3nkeYV{MS:FeXPsbY4hSjFiKF2xJJRwKFZ2M{OgdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiC|ZkmgZ4VtdHNiYYSgNUB2VSC3c3nu[{BTSi2FVF[gZZMhe3Wkc4TyZZRmKGK7IH\pcJRmeiCkaX7kbY5oKGG|c3H5 M3LZbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUW3OFMxLz5{OEW1O|Q{ODxxYU6=
sf9 MUjGeY5kfGmxbjDhd5NigQ>? NUL5eVllOSC3TR?= M1XEZmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzJiKF2xJJRwKEx{OUigdoV{cWS3ZYOpM2N6[2yrbjDFNUApVTFidH:gRVM6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{BifCBzIIXNJJV{cW6pIGLCMWNVTiCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? M3S2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUW3OFMxLz5{OEW1O|Q{ODxxYU6=
sf9 NGrZRotHfW6ldHnvckBie3OjeR?= NVGzdHY6OSC3TR?= M2TZbmlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SvTIl{Pi22YXfn[YQhSXW{b4LhJGEhME1zIITvJHM1ODNicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC|ZkmgZ4VtdHNiYYSgNUB2VSC3c3nu[{B1\XS{YTjMVnJNW0yJKTDhd{B{fWK|dILheIUh[nliZnnseIVzKGKrbnTpcoch[XO|YYm= MkjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
sf9 MVvGeY5kfGmxbjDhd5NigQ>? M{fMfVEhfU1? M4TSbmlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SteIFo\2WmIFH1do9z[SCEIDjNNUB1dyCVMkegdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiC|ZkmgZ4VtdHNiYYSgNUB2VSC3c3nu[{BETEN{NVOt[IVzcX[nZDDw[ZB1cWSnIHHzJJN2[nO2cnH0[UBjgSCoaXz0[ZIh[mmwZHnu[{Bie3OjeR?= MnXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
HT22 NX;vOVBMTnWwY4Tpc44h[XO|YYm= MXexNEB2VQ>? M{PCdVI1KGi{cx?= MYLJcohq[mm2aX;uJI9nKEeVS{OtcYVlcWG2ZXSgZoV1[SClYYPlbY4heGixc4Doc5J6dGG2aX;uJIlvKG2xdYPlJGhVOjJiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kBOTzF|Mh?= NGXuOHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm5PFQ1Oyd-MkK5PVg1PDN:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p21 / p27 ; 

PubMed: 27510556     


In BIO treatment of cardiac fibroblasts for 1 day, the protein levels of phosphorylated Akt, p21, and p27 were assessed.

p-β-catenin / β-catenin ; 

PubMed: 27211495     


ERKi and GSK3i differently regulate PI3K/Akt and β-catenin pathways. U0126 increased while BIO decreased Akt phosphorylation after 24 hours of treatment. BIO prevented β-catenin phosphorylation leading to intact β-catenin accumulation, while U0126 only had a marginal effect.

FoxO3a / FoxO1 / p-FoxO3a / p-FoxO1 ; 

PubMed: 27211495     


U0126 markedly increased the phosphorylation of Akt downstream targets FOXO1 and FOXO3a, while BIO decreased it.

27510556 27211495
Immunofluorescence
pAKT / p21 / p27 ; 

PubMed: 27510556     


Protein expressions of pAkt, p21 and p27 were determined by immunofluorescence staining in cardiac fibroblasts treated with BIO for 1 day. *p < 0.05, t-test. Scale bar = 100 μm.

TNF-α; 

PubMed: 24286133     


Detection of TNF-α protein expression by immunofluorescence microscopy. Nucleus pulposus cells were cultured with or without 1.0 μM BIO for 24 h, fixed, and stained with an antibody against c-fos. Left: cells stained with an antibody to TNF-α; middle: cells stained with 4′,6-diamidino-2-phenylindole (DAPI), to identify healthy nuclei; right: cells stained with an antibody to TNF-α and with DAPI. Scale bar, 50 μm (original magnification, 20×).

E-cadherin / Nanog ; 

PubMed: 25538040     


hESCs were treated with either vehicle (Veh) or BIO for 6 hours. Twenty-four hours after removal of BIO, hESCs exhibit thick and compact colonies that express higher levels of E‐cadherin (E‐cad) and Nanog.

Oct3/4; 

PubMed: 25538040     


hESCs were treated with either vehicle (Veh) or BIO for 6 hours. Twenty‐four hours after removal of BIO, hESCs exhibit thick and compact colonies that express higher levels of E‐cadherin (E‐cad) and Oct3/4. In contrast, long-term BIO treatment leads to opposing results. Scale bar = 20 µm.

27510556 24286133 25538040
Growth inhibition assay
Cell proliferation ; 

PubMed: 27510556     


The increase in cardiomyocyte proliferation after treatment with BIO for 4 days was also confirmed by MTT assay.

27510556
体内研究 BIO处理小鼠移植瘤模型,抑制黑色素瘤生长。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

激酶实验:

在Buffer A 或 C中在30°C下进行激酶活性检测,ATP 终浓度为15 μM。减去空白值,活性计算为在10分钟温育期间渗透的皮摩尔磷酸盐。使用适当的DMSO稀释液作为对照。在一些情况下通过SDS-PAGE后放射自显影测评底物的磷酸化。通过亲和层析法,从猪脑中纯化GSK-3α/β。检测中, 在15 μM[γ-32P] ATP (3,000 Ci/mmol;1 mCi/ml) 存在时,含5 μl 40 μM GS-1肽, 一种特异性GSK-3底物(YRRAAVPPSPSLSRHSSPHQSpEDEEE)的1 mg BSA/ml 10 mM DTT在buffer A中按1/100稀释,终体积为30 μl。在30°C下温育30分钟后,25 μl上清液等分试样点样到2.5×3 cm Whatman P81磷酸纤维素纸片上,20秒后,过滤器在10 ml磷酸/升水的溶液中洗涤5次(每次至少5分钟)。在1 ml ACS闪烁液存在时,对湿的过滤器进行计数。
细胞实验:[1]
- 合并
  • Cell lines: COS1, Hepa 或 SH-SY5Y 细胞
  • Concentrations: ~10 μM
  • Incubation Time: 12 或 24 小时
  • Method: COS1, Hepa (野生型, CEM/LM AhR 缺陷和 ELB1 ARNT 缺陷), 或 SH-SY5Y细胞在6 cm 培养皿中生长,培养基为含10%胎牛血清的DMEM培养基。当细胞密度达到〜70%汇合上,IO (5 μM), BIO (5 或 10 μM), MeBIO (5或50 μM), LiCl (20或40 mM), 或模拟液 (DMSO, 终浓度为0.5% )加入到培养基中。12 小时(SH-SY5Y) 或24小时后 使用裂解缓冲液(1% SDS, 1 mM原钒酸钠, 10 mM Tris [pH 7.4])裂解仍在实验板上的细胞。裂解液通过26G针头数次,在10,000×g下离心5分钟,调整到相等蛋白质浓度。上样约8 μg每种样品,用于免疫印迹分析。增强的化学发光是用于检测。使用如下一抗:小鼠anti-β-catenin CT(识别总β-catenin), 小鼠anti-phospho-β-catenin(识别去磷酸化的β-catenin), 小鼠anti-GSK-3β, 小鼠anti-GSK-3 phosphoTyr216, 兔anti-AhR(芳香烃受体), 及兔anti-Actin。
    (Only for Reference)
动物实验:[4]
- 合并
  • Animal Models: 小鼠
  • Dosages: 50 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 71 mg/mL (199.34 mM)
Water Insoluble
Ethanol '6 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+50%ddH2O
3 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 356.17
化学式

C16H10BrN3O2

CAS号 667463-62-9
储存条件 粉状
溶于溶剂
别名 GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04276857 Not yet recruiting Device: Irreversible electroporation (NanoKnife® ) Locally Advanced Pancreatic Cancer|Irreversible Electroporation University of Saskatchewan April 1 2022 Not Applicable
NCT04461301 Not yet recruiting Procedure: Multimodal Prehabilitation Frail Elderly Syndrome|Major Surgery University Hospital Inselspital Berne|University of Bern February 1 2022 Not Applicable
NCT05085730 Not yet recruiting Device: InMode Morpheus8 System Aging University of Texas Southwestern Medical Center February 1 2022 Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

GSK-3 Signaling Pathway Map

相关GSK-3产品

Tags: 购买BIO | BIO供应商 | 采购BIO | BIO价格 | BIO生产 | 订购BIO | BIO代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID